Il nostro standard di qualità: qualità lotto dopo lotto

Avextra è sinonimo di farmaci a base di cannabis di alta qualità. La nostra chiave del successo: la coltivazione in Portogallo e la combinazione di tradizione e alta tecnologia. Per saperne di più, guardate il video con il nostro CMO David Reckeweg-Lecompte.

Podcasts

Neil Smith è ospite da Planted con Sara Payan.

Sara Payan parla con Neil Smith, COO di Avextra, della situazione della cannabis in Europa e dei nuovi sviluppi della ricerca. Qui trovi l’intervista in inglese.

Comunicati stampa

Qui trovate gli ultimi comunicati stampa di Avextra.

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

In Folge einer Krebsbehandlung leiden 60-80% aller Onkologiepatientinnen und -patienten an  Chemotherapie-induzierten neuropathischen Schmerzen (CINP) in Form von bleibenden Schmerzen und Taubheitssymptomen – eine schwerwiegende Beeinträchtigung ihrer Lebensqualität. Die Deutsche…

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten klinischen Studie für Onkologiepatient:innen. Zum…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Auf dem virtuellen Deutschen Schmerz und Palliativtag im März haben Avextra und die Deutsche Gesellschaft für Schmerzmedizin (DGS) in einem Symposium ihre Pläne für eine gemeinsame prospektive, nicht-interventionelle, 12-wöchige Parallelgruppenstudie…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Heute ist ein historischer Tag in Deutschland, an dem große Fortschritte bei der Entstigmatisierung der Cannabispflanze gemacht wurden. Martha Lurther, CSO bei Avextra, teilt ihre Gedanken zu den deutschen Plänen.…

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to…

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

Strategic partnership deepens Research & Development of medicinal cannabis in areas such as clinical trials, development of medical devices, and extraction methodologies.  Avextra will actively participate in the supervision of…

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…

Germany unveils scaled-down recreational cannabis legalization plan

Germany unveils scaled-down recreational cannabis legalization plan

Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

UFFICIO STaMPa

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

IT